MEM-288

AXP000041.1 · Oncolytic virus

Platform
adenovirus (Ad5, IFN-beta and chimeric CD40 ligand-armed)
Originator
Memgen
Sponsor
Memgen

Names

NameTypeSource
MEM-288preferred name, codecurator, ncit

Virus

Role
Oncolytic
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Strain
Ad5 (MEM-288)
Replication
conditionally replicating
Modifications
armed with IFN-beta and a chimeric membrane-stable CD40 ligand (MEM40)
Transgenes
IFNB1, chimeric CD40 ligand (MEM40)
Route
intratumoral
Source
evidence

Cross-references

NCI Thesaurus
C185120

Approvals

No regulatory approval recorded.

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT05076760MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid TumorsRecruitingPhase 12022-04-212027-0240Advanced Cancer; Cutaneous Squamous Cell Carcinoma; Head and Neck Cancer; Melanoma; Merkel Cell Carcinoma; Metastatic Cancer; Non Small Cell Lung Cancer; Pancreatic Cancer; Solid Tumor; Triple Negative Breast Cancer

Recent changes

No changes recorded in its trials yet.

Clinical papers

No confirmed clinical papers yet.

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 39276533Oncolytic adenovirus MEM-288 encoding membrane-stable CD40L and IFNβ induces an anti-tumor immune response in high grade serous ovarian cancer.Neoplasia (New York, N.Y.)2024name in title: MEM-288
PMID 36757308Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity.Cancer immunology research2023name in abstract: MEM-288

NIH grants

ProjectTitleOrganisationPIYearsLinked by
R01CA283730Defining impact of in situ activation of CD40 and type 1 interferon signaling on theTME and systemic T cell immunity in murine models and cancer patientsH. LEE MOFFITT CANCER CTR & RES INSTBEG, AMER AZIZ2024–2026name in abstract: MEM-288

Notes

Conditionally replicating adenovirus encoding human IFN-beta and a chimeric membrane-stable CD40 ligand (MEM40). Phase I NCT05076760, intratumoral, with nivolumab.

How to cite

MEM-288 (AXP000041.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000041.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.